No registrations found.
ID
Source
Brief title
Health condition
GHB use disorder, GHB addiction
Sponsors and support
Intervention
Outcome measures
Primary outcome
To monitor the achievability and viability of the instruction guide.
Secondary outcome
To evaluate the instruction guide and to distinguish subgroup of patients the following data will be retrieved from the patient’s file: relapse in GHB-use either duration of abstinence after detoxification, craving, drop-out and duration of treatment, psychiatric problems, quality of sleep, social situation, cognitive functioning and quality of life.
Background summary
A instruction guide was developed to reduce relapse in GHB-use after detoxification. This instruction guide will be tested in the clinical practice by a pilotstudy. Participants will be recruited at two addiction treatment centres in the Netherlands: Arkin and Novadic-Kentron.
Study objective
Use of gamma-hydroxybutyrate (GHB) can lead to severe dependence or addiction. Patients often relapse in GHB use after detoxification. NISPA, Trimbos Institute and Bonger Institute are developing an instruction guide for relapse management. A systematic inventory of available literature and existing interventions was carried out for the development of this guideline. Results were discussed twice with patients, their significant others and professionals by conducting focus-groups. This procedure has resulted in a draft version of the guideline GHB relapse management which will now be tested in the clinical practice. Therefore, a pilot study has been set up at Novadic-Kentron and Jellinek.
Study design
3-months and 6-months after inclusion patients and their clinician will be interviewed. Data retrieved from patient’s file are included in the instruction guide (e.g. MATE-1, GHB-questionnaire, VAS-craving, DASS, MoCa, EQ-5D) and used for monitoring treatment.
Intervention
The instruction guide contains interventions, questionnaires for screening, diagnostics and monitoring, and helping instructions for professionals to reduce the risk of relapse in GHB-use after detoxification. Interventions are tailored and applied depending on patient’s need for care.
Inclusion criteria
Patients diagnosed with a GHB use disorder according to DSM 5; Patients applying for help in one of the participating treatment programs during the study period (Arkin or Novadic-Kentron).
Exclusion criteria
Being under the age of 18 years; insufficient knowledge of the Dutch language; severe psychiatric co-morbidity that would preclude to take part in the process and adherence to the instruction guide; and no informed consent to participate in the pilotstudy.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL6776 |
| NTR-old | NTR7645 |
| Other | ZonMw : 531004003 |